Supplementary Table 6. The monthly proportion of glomerulonephritis at Severance Hospital during the COVID-19 pandemic period (after February 2022) based on the ARIMA models

Pathologic finding	AIC	BIC	ARIMA model	Ljung-Box test p-value	Step change (95% CI)	Slope change (95% CI)
Total	−10.35	4.23	(1,0,0)(0,0,1) [12]	0.9921	0.089 (−0.233 to 0.411)	−0.009 (−0.056 to 0.037)
AIN	143.44	155.59	(0,0,0)(1,0,0) [12]	0.8223	0.583 (−0.110 to 1.275)	−0.014 (−0.114 to 0.086)
ATI	133.1	145.25	(0,0,0)(1,0,0) [12]	0.1597	−0.049 (−0.696 to 0.597)	0.018 (−0.076 to 0.112)
IgAN	86.65	96.37	(0,0,0)	0.2823	0.232 (−0.265 to 0.730)	−0.048 (−0.121 to 0.024)
MN	283.83	295.92	(0,1,1)(1,0,0) [12]	0.0119	−0.622 (−2.289 to 1.043)	0.192 (−0.039 to 0.423)
Nonspecific histology	264.13	276.29	(0,0,1)	0.4471	−0.456 (−2.183 to 1.270)	0.077 (−0.173 to 0.326)
Other nephropathies	306.87	316.6	(0,0,0)	0.7659	−0.781 (−2.627 to 1.066)	0.121 (−0.147 to 0.389)
IC-GN	227.15	236.87	(0,0,0)	0.5998	0.834 (−0.315 to 1.982)	−0.064 (−0.231 to 0.102)
Pauci-immune crescentic GN	231.44	243.6	(0,0,0)(0,0,1) [12]	0.6303	−0.521 (−1.683 to 0.641)	0.011 (−0.157 to 0.179)
Podocytopathy	159.13	171.28	(0,0,1)	0.2782	0.218 (−0.725 to 1.162)	−0.022 (−0.159 to 0.114)
Thrombotic microangiopathy	123.91	33.63	(0,0,0)	0.4586	−0.220 (−0.841 to 0.401)	0.000 (−0.090 to 0.090)

AIC, Akaike's information criterion; AIN, acute interstitial nephritis; ARIMA, autoregressive integrated moving average; ATI, acute tubular injury; BIC, Bayes information criterion; CI, confidence interval; COVID-19, coronavirus disease 2019; GN, glomerulonephritis; IC-GN, immune complex-mediated GN; IgAN, immunoglobulin A nephropathy; MN, membranous nephropathy.